Affymax (AFFY) On Watch Into PDUFA
Tweet
Share
E-mailGet Alerts AFFY Hot Sheet
Join SI Premium – FREE
Biotech traders are keeping close eye on Affymax, Inc. (NASDAQ: AFFY) today, the FDA PDUFA date for peginesatide.
In December, an FDA panel voted 15 to 1, with 1 abstention, that peginesatide demonstrated a favorable benefit/risk profile for use in the treatment of dialysis patients with anemia due to chronic kidney disease (CKD).
With shares up about 130% since that time, investors may have the urge to take profits into the news. However, one analyst recent said shares should continued to be bought and sees 80% chance of approval. History offers promising insights for a dialysis launch with product attributes like those of peginesatide, the firm notes.
Shares of AFFY are up 1.2 percent in morning action.
In December, an FDA panel voted 15 to 1, with 1 abstention, that peginesatide demonstrated a favorable benefit/risk profile for use in the treatment of dialysis patients with anemia due to chronic kidney disease (CKD).
With shares up about 130% since that time, investors may have the urge to take profits into the news. However, one analyst recent said shares should continued to be bought and sees 80% chance of approval. History offers promising insights for a dialysis launch with product attributes like those of peginesatide, the firm notes.
Shares of AFFY are up 1.2 percent in morning action.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
- Keenova doses first patient in Phase 3 hammer toe drug trial
- FDA clears path for Protagenic's PT00114 anxiety drug IND submission
Create E-mail Alert Related Categories
FDA, Trader TalkRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
